Nektar Therapeutics Grants Stock Options to New Employees
Nektar Therapeutics announced on July 24, 2026, that it granted stock options to purchase 36,000 shares of common stock to 23 newly hired employees under its 2025 Inducement Plan.
San Francisco, CA – Nektar Therapeutics (NASDAQ: NKTR) announced on July 24, 2026, that its Organization and Compensation Committee granted stock options to purchase an aggregate of 36,000 shares of its common stock to 23 newly hired employees. The grants were made under Nektar's 2025 Inducement Plan.
The stock options were issued with an exercise price of $64.84 per share, matching the closing price of Nektar's common stock on July 20, 2026. These options have an eight-year term and will vest over a four-year period. One-quarter of the shares will vest on the first anniversary of the grant date, with the remainder vesting monthly over the subsequent three years, contingent upon continued employment with Nektar.
The Inducement Plan is designed to provide equity awards specifically to individuals not previously employed by Nektar, serving as a material inducement for them to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The plan documentation and individual stock option agreements govern the terms and conditions of these grants.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and chronic inflammatory diseases. The company's lead product candidate is rezpegaldesleukin (REZPEG, NKTR-358), a regulatory T cell stimulator. It is currently in a registrational program for atopic dermatitis and planned for a similar program for alopecia areata, with ongoing evaluation in a Phase 2 trial for Type 1 diabetes.